During the plenary session at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, results were presented for NADINA, a phase 3 trial investigating neoadjuvant ipilimumab plus nivolumab for patients with resectable stage III melanoma. NADINA is the first phase 3 trial to evaluate neoadjuvant immunotherapy against standard of care in melanoma, as well as the first phase 3 trial in oncology to investigate a neoadjuvant regimen consisting of immunotherapy alone. After returning from the meeting, Dr. Matthew Hadfield, Oncology Data Advisor Editorial Board member and Medical Oncologist at Brown University, sat down to delve into the groundbreaking significance of these results for patients with melanoma.

Listen to hear more about:
• The recent paradigm shift towards using immunotherapy prior to surgical resection in melanoma
• The NADINA trial design and dosing of ipilimumab (a CTLA-4 inhibitor) in combination with nivolumab (a PD-1 inhibitor) followed by total lymph node dissection, versus a comparator arm of adjuvant nivolumab alone
• The event-free survival and major pathological response results seen in the immunotherapy combination arm
• Toxicities with the combination and the need to have risk-benefit conversations with patients
• Implications for how these results will impact practice
• How this research will be applicable in the broader field of oncology in the future
• And more!

свернуть